Search

Your search keyword '"Richard D. Kim"' showing total 94 results

Search Constraints

Start Over You searched for: Author "Richard D. Kim" Remove constraint Author: "Richard D. Kim" Journal journal of clinical oncology Remove constraint Journal: journal of clinical oncology
94 results on '"Richard D. Kim"'

Search Results

1. Biomarker analysis from a phase I/I1b study of regorafenib and nivolumab (rego/nivo) in microsatellite stable (MSS) colorectal cancer (CRC)

2. A phase II study of atezolizumab (ATEZO) and bevacizumab (BEV) in combination with Y90 TARE in patients (pts) with hepatocellular carcinoma (HCC): Y90+/- BEAT

3. Biomarker analysis to predict response in patients with metastatic mismatch repair proficient colorectal cancer treated with regorafenib and nivolumab

4. The role of socioeconomic deprivation in gastrointestinal cancer clinical trial enrollment at an NCI-designated comprehensive cancer center

5. Effect of immunotherapy on the survival outcomes in tumor mutational burden-high (TMB-H) microsatellite stable (MSS) metastatic colorectal cancer (mCRC): A single-institution experience

6. An open-label, multicenter, randomized phase II study of atezolizumab and bevacizumab with Y90 TARE in patients with unresectable hepatocellular carcinoma (HCC)

7. Pembrolizumab (pembro) plus mFOLFOX7 or FOLFIRI for metastatic colorectal cancer (CRC) in KEYNOTE-651: Long-term follow-up of cohorts B and D

8. Pembrolizumab (pembro) plus binimetinib (bini) with or without chemotherapy (chemo) for metastatic colorectal cancer (mCRC): Results from KEYNOTE-651 cohorts A, C, and E

9. Efficacy and safety of NT-I7, long-acting interleukin-7, plus pembrolizumab in patients with advanced solid tumors: Results from the phase 2a study

10. Characterization of NTRK alterations in metastatic colorectal cancer

11. Clinical and molecular characterization of fusion genes in colorectal cancer

12. Disparity of treatment-related adverse events and outcome in patients with early-onset metastatic colorectal cancer (mCRC)

13. Core homologous recombination mutations and improved survival in nonpancreatic GI cancers

14. A phase II study of TAS-102 (FTD/TPI) in combination with ramucirumab (RAM) in advanced, refractory gastric (GC) or gastroesophageal junction (GEJ) adenocarcinomas (GEAs)

15. Association of BRAF V600E mutation with survival in patients with metastatic mismatch repair-deficient colorectal cancer

16. Updated results of a phase 1b study of regorafenib (REG) 80 mg/day or 120 mg/day plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC)

17. A phase 1 study of TAK-164, an anti-guanylyl cyclase C (GCC) antibody-drug conjugate (ADC), in patients (pts) with advanced gastrointestinal (GI) cancers expressing GCC

18. Efficacy of olaparib therapy in metastatic pancreatic ductal adenocarcinoma (PDAC) with homologous recombination deficiency (HRD)

19. Investigate the efficacy of immunotherapy for treatment of pancreatic adenocarcinoma (PDAC) with mismatch repair deficiency (dMMR)

20. A phase II study of atezolizumab (ATEZO) and bevacizumab (Bev) in combination with Y90 TARE in patients (Pts) with hepatocellular carcinoma (HCC)

21. Results of a phase Ib study of regorafenib (REG) 80 mg/day plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC)

22. Results of biomarker analysis from phase II trial of nivolumab in refractory biliary tract cancer

23. Association between post-treatment (tx) alpha-fetoprotein (AFP) reduction and outcomes in real-world (rw) U.S. patients (pts) with advanced HCC (aHCC)

24. Outcomes of Lynch syndrome (LS) patients treated with immune checkpoint inhibitors (ICI)

25. Phase Ib study of regorafenib (REG) plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC)

26. Phase II study of copanlisib in combination with gemcitabine and cisplatin in advanced cholangiocarcinoma

27. Comparative efficacy of second-line treatments for advanced hepatocellular carcinoma: A network meta-analysis

28. Phase I study of preoperative capecitabine and lenvatinib with external radiation therapy in locally advanced rectal adenocarcinoma

29. A phase II study of TAS-102 in combination with ramucirumab in advanced, refractory gastric or gastroesophageal junction (GEJ) adenocarcinoma

30. Final analysis of phase II trial of regorafenib (REG) in refractory advanced biliary cancers (BC)

31. A phase II study of nivolumab in patients with advanced refractory biliary tract cancers (BTC)

32. Determining optimal follow up for patients with anal cancer following chemoradiation

33. Dose intensity of nab-paclitaxel and gemcitabine chemotherapy in metastatic pancreatic cancer

34. Phase I study of preoperative capecitabine and lenvatinib with external radiation therapy in locally advanced rectal adenocarcinoma

35. Impact of sarcopenia on outcomes in patients with rectal carcinoma treated with trimodality therapy

36. Phase I study of tramatinib combined with sorafenib in patients (pts) with advanced hepatocellular cancer (HCC)

37. Pathologic outcomes of systemic therapy followed by stereotactic body radiation therapy (SBRT) for pancreatic cancer (PC) in a novel lateral decubitus treatment position

38. Integrated profiling the patterns of pathologic response to neoadjuvant chemoradiation and the genomic-based radiation sensitivity in rectal cancer

40. Phase II study of copanlisib (BAY 80-6946) in combination with gemcitabine and cisplatin in advanced cholangiocarcinoma

41. Relationship between tumor-infiltrating lymphocytes (TIL) and absolute lymphocyte count (ALC) or lymphocyte to neutrophil ratio (LTN) in cholangiocarcinoma (CCA)

42. Final report: A phase I trial of BYL719 in combination with gemcitabine and nab-paclitaxel in locally advanced and metastatic pancreatic cancer

43. Ensituximab (E) in patients (pts) with refractory metastatic colorectal cancer (mCRC): Results of a phase I/II clinical trial

44. SWOG S1310: Randomized phase II trial of single agent MEK inhibitor trametinib vs. 5-fluorouracil or capecitabine in refractory advanced biliary cancer

45. Phase II study of first-line radioembolization with yttrium-90 glass microspheres for intrahepatic cholangiocarcinoma

46. Prognostic value of CD8+CD45RO+ tumor-infiltrating lymphocytes (TIL) and PD-L1 in cholangiocarcinoma

47. Survival analysis of yttrium-90 radioembolization for unresectable intrahepatic cholangiocarcinoma

48. Impact of duodenal invasion on outcomes in patients with pancreatic cancer treated with stereotactic body radiotherapy

49. Phase 1/2 study of durvalumab and tremelimumab as monotherapy and in combination in patients with unresectable hepatocellular carcinoma (HCC)

50. Clinical outcomes of patients with solid tumor enrolled in phase 1 clinical trials

Catalog

Books, media, physical & digital resources